

11 August 2016

Company Announcements Office
Australian Securities Exchange

Nanosonics appoints Dr Steven Farrugia as Senior Vice President Design and Development

Nanosonics (ASX: NAN) is pleased to announce the appointment of Dr Steven Farrugia to the position of Senior Vice President Design and Development.

Steven brings a wealth of experience having held senior executive and leadership roles in applied research and technology development as well as new product development for over 20 years at ResMed. During his time at ResMed Steven has held the positions of Director, Research & Technology Development, Vice President Product Development, Vice President Technology, Applied Research and Vice President of Supplier Innovation.

An inventor of close to 300 granted and pending patents, Steven has been identified as one of Australia's Top 10 Inventors in the Australian Medical Device Industry.

Steven holds a PhD in Electrical Engineering and is an Adjunct Professor in the Faculty of Engineering and Information Technologies at The University of Sydney.

'We are delighted to welcome Steven to the executive management team at Nanosonics. Steven's extensive experience as a research and product development professional adds further strength to our existing capabilities in new product development which is a core focus of the Company. Reporting directly to me and working closely with Dr Ron Weinberger, who is responsible for research into new technologies and subsequent product pipeline, Steven will have responsibility for the design and development of Nanosonics' product portfolio in accordance with our new product pipeline.' said Michael Kavanagh, Nanosonics' Chief Executive Officer and President.

"It is wonderful to be joining the Nanosonics team at this exciting stage of the Company's development. The area of infection prevention is not only very interesting but extremely important and the opportunities to bring new innovations to market are tremendous. I look forward to working with the whole Nanosonics team to deliver on its product innovation objectives and bringing new innovative solutions to the infection prevention community." said Dr Farrugia.

Michael Kavanagh
CEO / President

For more information please contact:

Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600

Kyahn Williamson, Investor Relations, Buchan Consulting on (03) 9866 4722

Ben Walsh, Media Relations, Buchan Consulting on (02) 9237 2801.

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. For more information about Nanosonics please visit www.nanosonics.com.au